Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Smoking

Smoking

Subtypes of Smoking

E-cigarette Use 1 Electronic Cigarette Use 1

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Smoking

180 trials tracked for Smoking: 40 in phase 3 or 4 and 8 with published results. The most-cited published study has 183 citations.

180Trials tracked
40Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 28 Phase 3 12 Phase 2 23 Phase 1 5 Other / NA 112
  1. Phase 4 A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers Completed · 183 cited
  2. Phase 4 The END Perioperative Smoking Pilot Study Completed · 62 cited
  3. Phase 3 Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers Completed · 30 cited
  4. Phase 4 Varenicline for Light Smokers Completed · 27 cited
  5. Phase 4 Smoking Tobacco and Drinking Study Completed · 26 cited
  6. Phase 3 CPT and Smoking Cessation Completed · 11 cited
Show 44 more trials
  1. Phase 4 UW-CTRI Triple Medication Smoking Cessation Study Completed · 2 cited
  2. Phase 3 Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke Completed
  3. Phase 4 Efficacy of Losartan in Preventing Progression of COPD Completed
  4. Phase 4 Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers Completed
  5. Phase 4 Varenicline Light Smoking Pilot Completed
  6. Phase 4 Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Completed
  7. Phase 4 Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) Completed
  8. Phase 4 Testing Integrative Smoking Cessation for HIV Patients Completed
  9. Phase 4 Treating Caregivers Who Smoke at AFCH Completed
  10. Phase 4 Identifying Treatments to Motivate Smokers to Quit Completed
  11. Phase 4 A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder Completed
  12. Phase 4 Combination Nicotine Replacement for Alcoholic Smokers Completed
  13. Phase 4 Evaluation of National Cancer Institute (NCI) Smoking Intervention Resources Completed
  14. Phase 4 Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT) Completed
  15. Phase 4 Long-term Varenicline Treatment for Smoking Cessation Completed
  16. Phase 4 Identifying Optimal Smoking Cessation Intervention Components (Cessation) Completed
  17. Phase 4 Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms Completed
  18. Phase 4 Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines Completed
  19. Phase 4 Pilot Study: Preoperative Nicotine Lozenges Completed
  20. Phase 4 Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts Completed
  21. Phase 4 Bupropion SR Plus Counseling for Smoking Cessation Completed
  22. Phase 4 Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial. Completed
  23. Phase 4 Melatonin in Smoke-induced Vascular Injury Completed
  24. Phase 4 Helping Those With Mental Illness Quit Smoking Completed
  25. Phase 4 Evaluation of Treatments to Improve Smoking Cessation Medication Adherence Completed
  26. Phase 3 Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation Completed
  27. Phase 3 Metabolism Informed Smoking Treatment: The MIST RCT Completed
  28. Phase 3 Smoking Termination Enhancement Project (STEP) Completed
  29. Phase 3 Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial Completed
  30. Phase 3 Varenicline and Bupropion for Smoking Cessation Completed
  31. Phase 3 Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation Completed
  32. Phase 3 Varenicline Treatment for Active Alcoholic Smokers Completed
  33. Phase 3 Chantix & Bupropion for Smoking Cessation Completed
  34. Phase 3 Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed
  35. Phase 2 STARS (Smoking Treatment And Remote Sampling) Study Completed
  36. Phase 2 Efficacy of Naltrexone in Women's Smoking Cessation Completed
  37. Phase 2 Testing Methylphenidate for Smoking Abstinence Completed
  38. Phase 2 Effect of Donepezil on Smoking Completed
  39. Phase 2 St. John's Wort for Tobacco Cessation Completed
  40. Phase 2 Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving Completed
  41. Phase 2 The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse Completed
  42. Phase 2 Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation Completed
  43. Phase 2 Modeling Stress-precipitated Smoking Behavior for Medication Development Completed
  44. Phase 2 Message Framing for Telephone Quitline Callers Completed

Showing the 50 most-cited and recently-updated of 180 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Smoking: what the trials found

Varenicline has demonstrated significant efficacy in reducing smoking prevalence at multiple time points. Specifically, a trial showed significantly lower point prevalence and prolonged smoking at both 12 weeks and 24 weeks compared to placebo 9. Additionally, Varenicline was associated with a higher number of participants achieving initial cessation within the first 7 days post-quit compared to other groups 7.

Nicotine replacement therapies (NRT) have been evaluated across various formats including patches and transdermal products. While specific outcomes for long-term abstinence were reported in some NRT studies, others showed no significant difference in self-reported 7-day point prevalence abstinence or latency to relapse when comparing different combinations of nicotine gum and patches 22. One study also assessed the usability and acceptability of a transdermal product 14.

Other pharmacological interventions include Bupropion, which was evaluated for smoking cessation [13, 20]. A trial involving active bupropion combined with counseling showed no significant difference in 7-day point prevalence abstinence at 6 months compared to other study arms 20. Additionally, Losartan was investigated regarding changes in emphysema on CT scans, but did not reach statistical significance 17.

Recent results — preliminary, needs further review

  • * THS use was associated with significantly lower carboxyhemoglobin (COHb) levels, lower total NNAL in urine, and lower white blood cell counts compared to other groups (p<0.001) 3. * BRB Lozenges showed a significant reduction in B[a]P adducts (p=0.0035) and 8-OXO-dG (p=0.026) in buccal cells, while no significant difference was found for HPB-releasing adducts 5. * A study on E-cigarette & Tobacco Use Treatment Intervention showed no statistically significant difference in self-reported 30-day abstinence between groups (p=0.91) 6. * Varenicline at a 0.5 mg dose was evaluated in a Phase 2 trial 2. * Flavored and unflavored little cigars/cigarillos were studied in a non-pharmacological context 4.

For the clinician treating this condition

  • Varenicline is supported by evidence for reducing point prevalence smoking at both 12 and 24 weeks, as well as increasing the likelihood of initial cessation within the first week [9, 7].
  • Nicotine replacement therapies (NRT) are established interventions, though some trials showed no significant difference in abstinence rates or relapse latency between different NRT combinations 22.
  • Bupropion combined with counseling was evaluated but did not show statistically significant differences in 6-month abstinence rates compared to other arms in the studied trial 20.

AI synthesis of 11 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia
Dermatology Meta-analysis
Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia Regional differences in health risks for hidradenitis suppurativa patients
This systematic review and meta-analysis examines the prevalence of hidradenitis suppurativa-associated comorbidities across North America, …
A meta-analysis reveals how hidradenitis suppurativa patients in North America, Europe, and the Middle East/Asia face different odds for dia…
May 1, 2026
Systematic review of 127 studies shows psychosocial interventions improve smoking cessation in pregnancy
Psychiatry Sys. Review
Systematic review of 127 studies shows psychosocial interventions improve smoking cessation in pregnancy Simple Support Helps Pregnant Women Quit Smoking, Study Shows
This systematic review and meta-analysis of 127 studies involving 47,361 participants evaluates psychosocial interventions for pregnant wome…
Supporting pregnant women to quit smoking with counseling or financial help can lead to healthier babies and fewer NICU admissions.
Cochrane Apr 21, 2026
Outbreak report summarizes patterns and characteristics of vaping-associated lung injury cases
Infectious Disease
Outbreak report summarizes patterns and characteristics of vaping-associated lung injury cases What did we learn from the vaping lung injury outbreak?
An observational outbreak report summarized patterns and characteristics of lung injury cases associated with e-cigarette use across multipl…
A 2019 wave of serious lung injuries swept across the United States, and all the cases had one thing in common: the people affected had used…
CDC Apr 6, 2026
215 possible severe pulmonary disease cases associated with e-cigarette use across 25 states
Pulmonology & Critical Care
215 possible severe pulmonary disease cases associated with e-cigarette use across 25 states What's behind 215 possible cases of severe lung disease linked to vaping?
A surveillance report identified 215 possible cases of severe pulmonary disease associated with electronic cigarette use across 25 states.
Health officials report 215 possible cases of severe lung disease across 25 states linked to electronic cigarette use.
CDC Apr 4, 2026